title: MondoA is highly overexpressed in acute lymphoblastic leukemia cells and modulates their metabolism, differentiation and survival.
abstract: Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. To identify novel candidates for targeted therapy, we performed a comprehensive transcriptome analysis identifying MondoA (MLXIP) - a transcription factor regulating glycolysis - to be overexpressed in ALL compared to normal tissues. Using microarray-profiling, gene-set enrichment analysis, RNA interference and functional assays we show that MondoA overexpression increases glucose catabolism and maintains a more immature phenotype, which is associated with enhanced survival and clonogenicity of leukemia cells. These data point to an important contribution of MondoA to leukemia aggressiveness and make MondoA a potential candidate for targeted treatment of ALL.
authors: Children's Cancer Research and Roman Herzog Comprehensive Cancer Center, Laboratory of Functional Genomics and Transplantation Biology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
authors: Caroline M
authors: CM
authors: Wernicke
authors: Günther H S
authors: GH
authors: Richter
authors: Beate C
authors: BC
authors: Beinvogl
authors: Stephanie
authors: S
authors: Plehm
authors: Anna M
authors: AM
authors: Schlitter
authors: Obul R
authors: OR
authors: Bandapalli
authors: Olivia
authors: O
authors: Prazeres da Costa
authors: Uwe E
authors: UE
authors: Hattenhorst
authors: Ines
authors: I
authors: Volkmer
authors: Martin S
authors: MS
authors: Staege
authors: Irene
authors: I
authors: Esposito
authors: Stefan
authors: S
authors: Burdach
authors: Thomas G P
authors: TG
authors: Grunewald
mesh_terms: D017209:Apoptosis / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D051778:Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / Q000235:genetics* / Q000378:metabolism / Q000502:physiology*; D002454:Cell Differentiation / Q000187:drug effects / Q000235:genetics*; D002470:Cell Survival / Q000187:drug effects / Q000235:genetics; D004353:Drug Evaluation, Preclinical; D020869:Gene Expression Profiling; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects; D056945:Hep G2 Cells; D006801:Humans; D019169:Jurkat Cells; D046228:Microarray Analysis; D009361:Neoplasm Invasiveness; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics* / Q000378:metabolism* / Q000473:pathology* / Q000503:physiopathology; D034741:RNA, Small Interfering / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D015854:Up-Regulation / Q000187:drug effects / Q000235:genetics
chemical_list: D051778:Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; C485496:MLXIP protein, human; D034741:RNA, Small Interfering